Cryosurgery As Primary Treatment for Localized Prostate Cancer

Overview

Journal Int Urol Nephrol

Publisher Springer

Specialty Nephrology

Date 2011 Apr 9

PMID 21475948

Citations 7

Authors

Huibo Lian

Hongqian Guo

Weidong Gan

Xiaogong Li

Xiang Yan

Wei Wang

Rong Yang

Feng Qu

Changwei Ji

Affiliations

Soon will be listed here.

Abstract

Objective: To present the early results of the use of third-generation cryotherapy as primary treatment for localized prostate cancer in China.

Patients And Methods: From January 2006 to December 2009, 102 patients underwent primary cryosurgery for clinically localized prostate cancer. All patients underwent a dual freeze-thaw cycle using third-generation cryotechnology with ultrathin 17-gauge cryoneedles.

Results: The prostate-specific antigen (PSA) level for all patients at the last follow-up visit was less than 0.5 ng/ml in 94 patients (92.2%) and 0.5 ng/ml or more in 8 (7.8%). One patient (1.0%) had recurrent prostate cancer confirmed by prostate biopsy and was treated with salvage cryotherapy. Seven other patients (6.9%) had an elevated PSA level after cryotherapy despite negative posttreatment biopsies and a metastatic evaluation. Of 102 patients, 1 patient was incontinent preoperatively. Of the remaining 101 patients, 4 patients (4.0%) developed mild incontinence requiring 1 to 2 pads per day. Urethral sloughing occurred in 5 of the 102 patients (4.9%) and in 1 of these patients (1.0%) required transurethral resection of sloughing. The rates of erectile dysfunction were 64.1%. No urethral strictures, rectourethral fistulas, urinary retention, or chronic pelvic pain was reported. The median inpatient stay after cryoablation was 3.2 days.

Conclusion: Early results suggest that cryotherapy offers a safe and effective alternative for the primary treatment of localized prostate cancer. Additional studies with longer follow-up are necessary to determine the sustained efficacy of this procedure.

Citing Articles

The incidence proportion of erectile dysfunction in patients treated with cryotherapy for prostate cancer: a meta-analysis.

Zhou J, Fang D, Xia S, Li T, Liu R Clin Transl Oncol. 2019; 21(9):1152-1158.

PMID: 30649710 DOI: 10.1007/s12094-019-02036-8.

Transperineal cryotherapy for unresectable muscle invasive bladder cancer: preliminary experience with 7 male patients.

Zhang Q, Zhang S, Zhang S, Wang W, Zhao X, Deng Y BMC Urol. 2017; 17(1):81.

PMID: 28888228 PMC: 5591566. DOI: 10.1186/s12894-017-0270-y.

Focal cryoablation for unilateral low-intermediate-risk prostate cancer: 63-month mean follow-up results of 41 patients.

Lian H, Zhuang J, Yang R, Qu F, Wang W, Lin T Int Urol Nephrol. 2015; 48(1):85-90.

PMID: 26531063 DOI: 10.1007/s11255-015-1140-8.

Salvage cryosurgery for locally recurrent prostate cancer after primary cryotherapy.

Chang X, Liu T, Zhang F, Zhao X, Ji C, Yang R Int Urol Nephrol. 2014; 47(2):301-5.

PMID: 25510358 DOI: 10.1007/s11255-014-0887-7.

Recent advances in imaging-guided interventions for prostate cancers.

Wu X, Zhang F, Chen R, Zheng W, Yang X Cancer Lett. 2014; 349(2):114-9.

PMID: 24769076 PMC: 4082995. DOI: 10.1016/j.canlet.2014.04.015.

References

Ellis D, Manny Jr T, Rewcastle J . Cryoablation as primary treatment for localized prostate cancer followed by penile rehabilitation. Urology. 2007; 69(2):306-10. DOI: 10.1016/j.urology.2006.10.024. View

Asterling S, Greene D . Prospective evaluation of sexual function in patients receiving cryosurgery as a primary radical treatment for localized prostate cancer. BJU Int. 2008; 103(6):788-92. DOI: 10.1111/j.1464-410X.2008.08042.x. View

Akdas A, Cevik I, Tarcan T, Turkeri L, Dalaman G, Emerk K . The role of free prostate-specific antigen in the diagnosis of prostate cancer. Br J Urol. 1997; 79(6):920-3. DOI: 10.1046/j.1464-410x.1997.00183.x. View

Robinson J, Donnelly B, Siever J, Saliken J, Ernst S, Rewcastle J . A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer: quality of life outcomes. Cancer. 2009; 115(20):4695-704. DOI: 10.1002/cncr.24523. View

Donnelly B, Saliken J, Brasher P, Ernst S, Rewcastle J, Lau H . A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer. Cancer. 2009; 116(2):323-30. DOI: 10.1002/cncr.24779. View

Han K, Belldegrun A . Third-generation cryosurgery for primary and recurrent prostate cancer. BJU Int. 2003; 93(1):14-8. DOI: 10.1111/j.1464-410x.2004.04547.x. View

Katz A, Rewcastle J . The current and potential role of cryoablation as a primary therapy for localized prostate cancer. Curr Oncol Rep. 2003; 5(3):231-8. DOI: 10.1007/s11912-003-0115-6. View

Jemal A, Thomas A, Murray T, Thun M . Cancer statistics, 2002. CA Cancer J Clin. 2002; 52(1):23-47. DOI: 10.3322/canjclin.52.1.23. View

Donnelly B, Saliken J, Ernst D, Brasher P, Robinson J, Rewcastle J . Prospective trial of cryosurgical ablation of the prostate: five-year results. Urology. 2002; 60(4):645-9. DOI: 10.1016/s0090-4295(02)01839-3. View

10.

Cohen J, Miller Jr R, Ahmed S, Lotz M, Baust J . Ten-year biochemical disease control for patients with prostate cancer treated with cryosurgery as primary therapy. Urology. 2008; 71(3):515-8. DOI: 10.1016/j.urology.2007.09.059. View

11.

Polascik T, Nosnik I, Mayes J, Mouraviev V . Short-term cancer control after primary cryosurgical ablation for clinically localized prostate cancer using third-generation cryotechnology. Urology. 2007; 70(1):117-21. DOI: 10.1016/j.urology.2007.03.027. View

12.

Benoit R, Cohen J, Miller Jr R . Cryosurgery for prostate cancer: new technology and indications. Curr Urol Rep. 2002; 1(1):41-7. DOI: 10.1007/s11934-000-0034-0. View

13.

de la Taille A, Benson M, Bagiella E, Burchardt M, Shabsigh A, Olsson C . Cryoablation for clinically localized prostate cancer using an argon-based system: complication rates and biochemical recurrence. BJU Int. 2000; 85(3):281-6. DOI: 10.1046/j.1464-410x.2000.00456.x. View

14.

Mouraviev V, Polascik T . Update on cryotherapy for prostate cancer in 2006. Curr Opin Urol. 2006; 16(3):152-6. DOI: 10.1097/01.mou.0000193393.54598.9f. View

15.

Makarov D, Trock B, Humphreys E, Mangold L, Walsh P, Epstein J . Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology. 2007; 69(6):1095-101. PMC: 1993240. DOI: 10.1016/j.urology.2007.03.042. View

16.

Robinson J, Saliken J, Donnelly B, Barnes P, Guyn L . Quality-of-life outcomes for men treated with cryosurgery for localized prostate carcinoma. Cancer. 1999; 86(9):1793-801. View

17.

Bahn D, Lee F, Badalament R, Kumar A, Greski J, Chernick M . Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. Urology. 2002; 60(2 Suppl 1):3-11. DOI: 10.1016/s0090-4295(02)01678-3. View

18.

Babaian R, Donnelly B, Bahn D, Baust J, Dineen M, Ellis D . Best practice statement on cryosurgery for the treatment of localized prostate cancer. J Urol. 2008; 180(5):1993-2004. DOI: 10.1016/j.juro.2008.07.108. View

19.

Cohen J . Cryosurgery of the prostate: techniques and indications. Rev Urol. 2006; 6 Suppl 4:S20-6. PMC: 1472869. View

20.

Long J, Bahn D, Lee F, Shinohara K, Chinn D, Macaluso Jr J . Five-year retrospective, multi-institutional pooled analysis of cancer-related outcomes after cryosurgical ablation of the prostate. Urology. 2001; 57(3):518-23. DOI: 10.1016/s0090-4295(00)01060-8. View